Cognitive Remediation and Social Recovery in Early Psychosis (CReSt-R): protocol for a pilot randomised controlled study.
Cognitive remediation
Early psychosis
Feasibility
Occupational function
Pilot
Psychosocial intervention
Social function
Social recovery
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
07
12
2021
accepted:
06
05
2022
entrez:
24
5
2022
pubmed:
25
5
2022
medline:
25
5
2022
Statut:
epublish
Résumé
Psychosis, even in its early stages, is associated with significant disability, causing it to be ranked ahead of paraplegia and blindness in those aged 18-35 in terms of years lived with disability. Current pharmacological and psychological interventions intervention have focused primarily on the reduction of positive symptoms (hallucinations and delusions), with little benefit to domains of psychosis such as cognitive difficulties and social and occupational functioning. The CReSt-R intervention trial is a single center, pilot randomised controlled study based at the National University of Ireland (NUI), Galway. The trial will recruit participants from four clinical sites with assessment and intervention completed by the primary NUI Galway team. The trial will explore the feasibility, acceptability, and effectiveness of a novel psychosocial intervention for early psychosis based on a combined cognitive remediation training and cognitive behavioural therapy approach focused on social recovery. Participants, aged 16-35 within the first 5 years of a diagnosed psychotic disorder, will be recruited from the Children and Adolescent Mental Health Service and the Adult Mental Health Services in the region. Cognitive remediation training (for improving cognition) and social recovery focused cognitive behavioural therapy, have both separately demonstrated effectiveness. This trial will evaluate the feasibility, acceptability, and explore the efficacy of a treatment approach that combines both approaches as part of an integrated, multicomponent intervention. Cognitive Remediation & Social Recovery in Early Psychosis (CReSt-R): ClincialTrials.gov Identifier NCT04273685. Trial registered Feb 18
Sections du résumé
BACKGROUND
BACKGROUND
Psychosis, even in its early stages, is associated with significant disability, causing it to be ranked ahead of paraplegia and blindness in those aged 18-35 in terms of years lived with disability. Current pharmacological and psychological interventions intervention have focused primarily on the reduction of positive symptoms (hallucinations and delusions), with little benefit to domains of psychosis such as cognitive difficulties and social and occupational functioning.
METHODS/DESIGN
METHODS
The CReSt-R intervention trial is a single center, pilot randomised controlled study based at the National University of Ireland (NUI), Galway. The trial will recruit participants from four clinical sites with assessment and intervention completed by the primary NUI Galway team. The trial will explore the feasibility, acceptability, and effectiveness of a novel psychosocial intervention for early psychosis based on a combined cognitive remediation training and cognitive behavioural therapy approach focused on social recovery. Participants, aged 16-35 within the first 5 years of a diagnosed psychotic disorder, will be recruited from the Children and Adolescent Mental Health Service and the Adult Mental Health Services in the region.
DISCUSSION
CONCLUSIONS
Cognitive remediation training (for improving cognition) and social recovery focused cognitive behavioural therapy, have both separately demonstrated effectiveness. This trial will evaluate the feasibility, acceptability, and explore the efficacy of a treatment approach that combines both approaches as part of an integrated, multicomponent intervention.
TRIAL REGISTRATION
BACKGROUND
Cognitive Remediation & Social Recovery in Early Psychosis (CReSt-R): ClincialTrials.gov Identifier NCT04273685. Trial registered Feb 18
Identifiants
pubmed: 35610711
doi: 10.1186/s40814-022-01064-6
pii: 10.1186/s40814-022-01064-6
pmc: PMC9126749
doi:
Banques de données
ClinicalTrials.gov
['NCT04273685']
Types de publication
Journal Article
Langues
eng
Pagination
109Subventions
Organisme : Health Research Board
ID : CDA-2018-001
Pays : Ireland
Informations de copyright
© 2022. The Author(s).
Références
Schizophr Res. 2009 Apr;109(1-3):1-9
pubmed: 19195844
Schizophr Res. 2015 Feb;161(2-3):188-93
pubmed: 25541138
Schizophr Res. 1995 Sep;17(1):5-13
pubmed: 8541250
Schizophr Res. 2020 Jan;215:49-53
pubmed: 31699627
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
J Psychiatr Res. 2011 May;45(5):626-9
pubmed: 21035130
Pilot Feasibility Stud. 2021 Jan 11;7(1):22
pubmed: 33431018
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
J Child Psychol Psychiatry. 2001 Feb;42(2):241-51
pubmed: 11280420
Schizophr Bull. 2021 Aug 21;47(5):1243-1253
pubmed: 33761534
Neuropsychol Rehabil. 2019 Apr;29(3):361-375
pubmed: 28316273
Psychol Med. 2017 Nov;47(15):2720-2730
pubmed: 28866988
Schizophr Bull. 2014 Jul;40(4):813-23
pubmed: 23728248
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Early Interv Psychiatry. 2018 Oct;12(5):879-885
pubmed: 27600941
BMJ Open. 2017 Feb 17;7(2):e013537
pubmed: 28213598
J Nerv Ment Dis. 2014 Jan;202(1):30-4
pubmed: 24375209
Stat Med. 1995 Sep 15;14(17):1933-40
pubmed: 8532986
Psychol Med. 2023 Apr;53(5):1787-1798
pubmed: 34474696
JAMA Psychiatry. 2020 Dec 1;77(12):1205-1206
pubmed: 32391857
BMC Psychiatry. 2011 Nov 23;11:185
pubmed: 22112008
J Psychiatr Res. 2017 Jul;90:67-77
pubmed: 28231496
Behav Cogn Psychother. 2016 May;44(3):288-305
pubmed: 26004421
Br J Psychiatry. 2017 Dec;211(6):350-358
pubmed: 28982659
Pilot Feasibility Stud. 2019 Nov 03;5:120
pubmed: 31700654
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
Schizophr Res. 2009 Jan;107(1):47-54
pubmed: 18930378
Clin Psychol Rev. 2012 Dec;32(8):724-40
pubmed: 23059624
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
JAMA Psychiatry. 2021 Aug 1;78(8):848-858
pubmed: 33877289
JAMA Psychiatry. 2018 Jun 1;75(6):555-565
pubmed: 29800949
Schizophr Bull. 2010 Sep;36(5):966-76
pubmed: 19386577
Psychol Med. 2009 Oct;39(10):1627-36
pubmed: 19335932
Psychiatry Res. 1997 Jul 4;71(2):105-13
pubmed: 9255855
J Pers Assess. 1984 Jun;48(3):306-7
pubmed: 16367530
J Eval Clin Pract. 2004 May;10(2):307-12
pubmed: 15189396
Psychol Med. 2018 Apr;48(5):751-764
pubmed: 28933314
Schizophr Res. 2019 Jan;203:3-11
pubmed: 28712968
Schizophr Bull. 2012 Sep;38(5):1092-104
pubmed: 21525166
Br J Psychiatry. 2008 Jul;193(1):77-8
pubmed: 18700225
J Clin Psychiatry. 2016 Feb;77 Suppl 2:8-11
pubmed: 26919052
Schizophr Res. 2006 Jul;85(1-3):142-50
pubmed: 16678388